REVB Q4 2023 Earnings — Revelation Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

REVBRevelation Biosciences, Inc.

$2M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37,574

Gross Profit

$18,78750.0% margin

Operating Income

-$2M-6190.2% margin

Net Income

-$2M-5862.8% margin

EPS (Diluted)

$-133.24

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$32,095

Balance Sheet

Total Assets

$12M

Total Liabilities

$6M

Stockholders' Equity

$7M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37,574	$0	—
Gross Profit	$18,787	-$6,262	+400.0%
Operating Income	-$2M	-$1M	-90.9%
Net Income	-$2M	-$1M	-82.4%